Abstract
The soluble dietary fiber polydextrose (PDX) is a randomly linked glucose oligomer containing small amounts of sorbitol and citric acid and is widely used in the food industry. However, whether PDX can prevent and treat obesity in high-fat diet (HFD)-fed mice has not been directly investigated, and further studies are needed to better understand the complex interactions among PDX, adipose tissue inflammation and the gut microbiota. In the present study, PDX reduced body weight, fasting blood glucose (FBG), adipose tissue accumulation, adipocyte hypertrophy, serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels in HFD-fed mice. Moreover, PDX alleviated serum lipopolysaccharide (LPS) levels and macrophage infiltration in epididymal adipose tissue and resulted in macrophage polarization toward the M2 phenotype. Gut microbiota analysis revealed that PDX promoted the growth of beneficial microbes such as Bacteroides, Parabacteroides, Alloprevotella, Muribaculum, Akkermansia, Ruminococcaceae_UCG-014 and UBA1819 in obese mice, which were negatively correlated with subcutaneous fat, epididymal fat, body weight, FBG, serum TC, HDL-C, LDL-C and LPS levels. Our results indicates that PDX can prevent and treat obesity in HFD-fed mice, specifically in alleviating glucolipid metabolism disorders and adipose tissue inflammation, which may be mediated by modulating the structure of the gut microbiota. Therefore, PDX may become a promising nondrug therapy for obesity.
Highlights
Obesity is a global health problem that is characterized by weight gain, fat accumulation, insulin resistance, chronic inflammation and gut microbiota dysbiosis (Canfora et al, 2019; Xu et al, 2021)
We aim to investigate the effects of PDX on glucolipid metabolism disorders, adipose tissue inflammation and the gut microbiota in high-fat diet (HFD)-fed mice, as well as the complex interactions among them
The results indicated that the HFD decreased glucose tolerance and insulin sensitivity in mice; notably, PDX supplementation increased glucose tolerance and improved HFD-induced insulin resistance (Figures 2E,F)
Summary
Obesity is a global health problem that is characterized by weight gain, fat accumulation, insulin resistance, chronic inflammation and gut microbiota dysbiosis (Canfora et al, 2019; Xu et al, 2021). Many studies have indicated that individuals with obesity are associated with an increased risk of coronavirus disease 2019 (COVID-19) morbidity and mortality, and obese patients with COVID-19 infection should be treated more aggressively (Hamer et al, 2020; Popkin et al, 2020; Sanchis-Gomar et al, 2020; Stefan et al, 2020). It is crucial and urgent for us to find effective therapies to prevent and treat obesity
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
